Citigroup
MTNB icon

Citigroup’s Matinas BioPharma MTNB Stock Holding History

Citigroup’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-84
Closed -$2.38K – 6320
2025
Q3 		$2.38K Buy
+84
New +$1.81K ﹤0.01% 5440
2023
Q1 		– Hold
0
– -$90 – 5734
2022
Q4 		– Hold
0
– – – 5642
2022
Q3 		– Hold
0
– – – 6152
2022
Q2 		– Hold
0
– – – 6504
2022
Q1 		– Hold
0
– – – 6510
2021
Q4 		– Hold
0
– – – 6007
2020
Q1 		– Sell
-13
Closed -$23K – 7713
2019
Q4 		$23K Buy
+13
New +$11.3K ﹤0.01% 6871
2018
Q3 		– Hold
0
– – – 7824
2018
Q2 		– Sell
-19
Closed -$8.23K – 7681
2018
Q1 		$35K Buy
19
+10
+111% +$7.93K ﹤0.01% 6412
2017
Q4 		$8K Buy
+9
New +$8.68K ﹤0.01% 7111
2017
Q3 		– Sell
-1
Closed -$1K – 7366
2017
Q2 		$1K Buy
+1
New +$2.01K ﹤0.01% 7173

Other funds holding MTNB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DRW Securities
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citigroup's MTNB Position: Q4 2025 in Review

Citigroup sold out of Matinas BioPharma (MTNB) in Q4 2025, closing a stake of 84 shares — an estimated $2.38K sold.

Citigroup first reported a position in MTNB in Q2 2017 and held it in 5 quarters. The position peaked at $35K in Q1 2018. 28 funds tracked by Wall St. Rank hold MTNB as of Q4 2025.

  • Citigroup reported no remaining Matinas BioPharma position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 84 Matinas BioPharma shares in Q4 2025, an estimated $2.38K.
  • Citigroup first reported a position in Matinas BioPharma in Q2 2017 and held it in 5 quarters.
  • Citigroup's Matinas BioPharma position peaked at $35K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.